Sanofi India Limited reported an 8% drop in net profit for Q2 FY26, falling to ₹76 crore from ₹82 crore a year earlier. Revenue from operations also declined 9% to ₹475.4 crore from ₹524 crore, according to its stock exchange filing.
Despite lower sales, the company’s EBITDA grew 12% to ₹134 crore, with the operating margin improving to 28% from 23%. Sanofi attributed the growth to cost optimisation and a better product mix. The company continues to focus on diabetes and cardiovascular treatments as part of its restructuring in India.
Alongside the results, the board announced an interim dividend of ₹75 per share for FY25, with November 7 set as the record date. Sanofi India also named Deepak Arora as Managing Director for a three-year term starting October 27, succeeding Rachid Ayari.
Arora, with over 30 years of global pharma experience, will drive Sanofi’s strategic vision in India. Shares of Sanofi India closed nearly flat at ₹4,747 on Wednesday. The stock has risen 22% this year, even as the Nifty Pharma index declined 4.5%.
